The CEO of C3 Therapeutics tells us how they're building a new class of antivirals, discusses a useful mental model for understanding biology, how to manage risk, and exciting emerging science
Gokul Kannan (C3 Therapeutics)
Gokul Kannan (C3 Therapeutics)
Gokul Kannan (C3 Therapeutics)
The CEO of C3 Therapeutics tells us how they're building a new class of antivirals, discusses a useful mental model for understanding biology, how to manage risk, and exciting emerging science